Purpose: This study aimed to provide an update and compare perioperative outcomes and complications of intracorporeal and extracorporeal urinary diversion following robot-assisted radical cystectomy using data from the multiinstitutional, prospectively maintained International Robotic Cystectomy Consortium database. Materials and Methods: We retrospectively reviewed the records of 2,125 patients from a total of 26 institutions. Intracorporeal urinary diversion was compared with extracorporeal urinary diversion. Multivariate logistic regression models using stepwise variable selection were fit to evaluate preoperative, operative and postoperative predictors of intracorporeal urinary diversion, operative time, high grade complications and 90-day hospital readmissions after robot-assisted radical cystectomy. Results: In our cohort 1,094 patients (51%) underwent intracorporeal urinary diversion. These patients demonstrated shorter operative time (357 vs 400 minutes), less blood loss (300 vs 350 ml) and fewer blood transfusions (4% vs 19%, all p <0.001). They experienced more high grade complications (13% vs 10%, p ¼ 0.02). Intracorporeal urinary diversion use increased from 9% of all urinary diversions in 2005 to 97% in 2015. Complications after this procedure decreased significantly with time (p <0.001). On multivariable analysis higher annual cystectomy volume (OR 1.02, 95% CI 1.01e1.03, p <0.002), year of robotassisted radical cystectomy (2013e2016 OR 68, 95% CI 44e105, p <0.001) and American Society of AnesthesiologistsÒ score less than 3 (OR 1.75, 95% CI Accepted for publication December 7, 2017. No direct or indirect commercial incentive associated with publishing this article. The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
1.38e2.22, p <0.001) were associated with undergoing intracorporeal urinary diversion. The procedure was associated with a shorter operative time of 27 minutes (p ¼ 0.001). Conclusions: The use of intracorporeal urinary diversion has increased in the last decade. A higher annual institutional volume of robot-assisted radical cystectomy was associated with intracorporeal urinary diversion as well as with shorter operative time. Although intracorporeal urinary diversion was associated with higher grade complications than extracorporeal urinary diversion, they decreased with time.
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THE use of RARC has witnessed a paramount increase in the last decade. 1 While RARC has been associated with improved perioperative outcomes such as blood loss, hospital stay and improved convalescence, much of the criticism has been attributable to the lack of tactile feedback and the longer operative time, especially with the intracorporeal approach to urinary diversion and also with construction of a continent reservoir. Consequently most surgeons have performed a hybrid approach with extracorporeal construction of urinary diversion.
Expertise and continuous refinement of the technique has decreased operative time and cost. 2 Consequently operative time has been identified as a quality measure for the surgical performance of RARC. 3, 4 In a recent study RARC and an intracorporeal ileal conduit were shown to be technically feasible without jeopardizing outcomes. 3, 5 On the other hand, intracorporeal neobladders are more technically challenging and time-consuming with a steep learning curve so that adoption has been slower and confined to high volume academic institutions. Nevertheless, several intracorporeal neobladder techniques were recently described with promising functional and oncologic outcomes. ICUD provides benefits in terms of a complete minimally invasive technique, including smaller incisions, reduced pain, decreased bowel related complications and a decreased risk of third space loss and fluid imbalance. 10, 11 We aimed to provide an update and compare the perioperative outcomes and complications of ICUD and ECUD following RARC using data from the multi-institutional, prospectively maintained IRCC database.
METHODS
We retrospectively reviewed the records of 2,432 patients from a total of 29 institutions who were included in the IRCC database (I-97906). Patients who had missing data on diversion approach or technique were excluded from study. The final cohort comprised 2,125 patients from a total of 26 institutions who were treated with RARC since 2005.
Data were reviewed on patient age, gender, BMI, ASAÒ score, preoperative characteristics (neoadjuvant chemotherapy, prior abdominal surgery and clinical staging), institutional volume, year of RARC, operative variables (diversion type and technique, operative time, estimated blood loss and blood transfusion), perioperative outcomes (complications, hospital readmissions, and hospital and intensive care unit stays) and pathological outcomes (staging, lymph node yield and soft tissue surgical margins). The techniques of RARC and urinary diversion, and followup differed among institutions. ICUD was compared with ECUD in terms of complications, survival and recurrence patterns.
Descriptive statistics were used to summarize the data. Univariable associations were statistically assessed by the Wilcoxon rank sum, the Pearson chi-square or the Fisher exact test. Univariate and multivariate (stepwise variable selection) logistic regression models were fit to evaluate preoperative, operative and postoperative predictors of ICUD, operative time, high grade complications and any readmission after RARC. The Kaplan-Meier method was applied to depict RFS, DSS and OS. Cox proportional hazards regression models were fit to evaluate predictors of survival outcomes. All tests were 2-sided with statistical significance considered at p 0.05. All statistical analyses were performed with SASÒ, version 9.4. fig. 3 ).
RESULTS

ICUD
Compared to patients who underwent ECUD those treated with ICUD included fewer with an ASA score of 3 or greater (44% vs 53%, p <0.001) but received neoadjuvant chemotherapy more frequently (25% vs 17%, p <0.001). Those treated with ICUD had shorter operative time (357 vs 400 minutes) and less blood loss (300 vs 350 ml), and received blood transfusion less frequently (5% vs 13%, all p <0.001). There was no significant difference in the receipt of a neobladder (21% vs 23%, p ¼ 0.32).
Patients treated with ICUD experienced complications more often (57% vs 43%, p <0.001), especially in month 1 after RARC (31% vs 19%, p <0.001). For DSS patients with a higher lymph node yield showed a marginal benefit (HR 0.97, 95% CI 12 Predictors of ICUD were annual RARC volume as well as the cystectomy era of 2013 to 2016 and ASA score less than 3. It is notable that ICUD was adopted earlier in Europe than in the United States. 4 Prior reports showed that a stepwise approach to RARC and pelvic LND allowed for safe incorporation of ICUD. 3 The technique of RARC (extended pelvic LND) has been optimized and with experience with human-robot interaction, ICUD became more popular with the development of multiple techniques for more complex intracorporeal neobladders. 7,9,10,13e15 A team approach combined with mentoring, especially during the early learning curve, will further reduce operative time and complications. 16 Although there was no significant difference in diversion type between ICUD and ECUD, the increased use of ICUD has been primarily noted for ileal conduits (from 2% in 2005 to 81% in 2016) compared to intracorporeal neobladders (from 7% in 2005 to 17% in 2016). The intracorporeal neobladder is more technically demanding, which may explain this pattern. Whether the approach to urinary diversion affects the choice of urinary diversion is still unclear. 17 With increased experience and comfort with the robotic platform RARC operative time has decreased with time. 18 ICUD was associated with shorter operative time in this study, in contrast to prior reports. 11 This could be due to increased comfort and experience with ICUD and flattening of the learning curve or to the additional time of undocking the robot and preparing the patient for ECUD, which adds to total operative time. Higher BMI and a neobladder may add to the complexity of RARC with more time spent in port placement, careful dissection and LND. 19, 20 Filson et al examined the factors that may contribute to operative time and divided them into modifiable factors such as LND extent, diversion type and technique, and nonmodifiable factors such as age and gender, in addition to institutional and surgeon factors. 21 They observed longer operative time for neobladders and for more extensive LND. Older patient age and the number of comorbidities were significantly associated with shorter operative time, which they explained by the fact that surgeons anticipate higher anesthetic complications and tend to operate faster in patients who are older and more ill. Female gender was also associated with longer operative time, which may be attributable to prior gynecologic procedures rather than to a true, gender related difference. 20 Higher annual RARC volume and a more recent cystectomy era were associated with shorter operative time. More experience and flattening of the learning curve associated with more procedures performed would lead to decreasing operative times. As in this study, higher surgical volume has been associated with shorter operative time for RC. 18, 21, 22 In an earlier report from IRCC of ICUD in 167 patients (18%) ICUD was associated with lower gastrointestinal and 90-day complication rates.
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The current study shows that patients who underwent ICUD had higher overall and high grade complications, especially in month 1 after RARC. We believe that the earlier experience was subject to patient selection bias. With increased use of ICUD and broadening of patient selection the actual burden of RARC rather than ICUD was observed. 4 Interestingly the incidence of high grade complications after ICUD decreased with time while it remained stable for ECUD. Moreover, on multivariable analysis prior abdominal surgery was the only significant predictor of high grade complications. Higher BMI and high grade complications were significantly associated with readmission. The approach to urinary diversion (ICUD vs ECUD) was not a significant predictor of either factor. About two-thirds of the complications necessitating reoperation after RARC develop beyond 3 months after RARC. Therefore, it is important to report readmissions and complications beyond 3 months to avoid underestimating the actual burden of the procedure. 23 There was a significant difference in RFS and DSS between the 2 approaches. In agreement with the robotic and open cystectomy literature survival outcomes after cystectomy are mainly driven by disease related factors, including pT stage, nodal status and positive surgical margins. 24e27 Patients treated with ECUD experienced more distant recurrences than those who underwent ICUD. In agreement with a prior report from IRCC 25 the incidence of peritoneal carcinomatosis and port site recurrence was low at 1% and 0.3%, respectively. Despite the statistical difference between ICUD and ECUD in extrapelvic lymph node metastasis and peritoneal carcinomatosis the small numbers limited any conclusions that could be made. Patients treated with ECUD experienced better OS at 3 and 5 years, likely because of the higher complication rate associated with ICUD, especially early in the ICUD experience. Nevertheless, the diversion approach was not significantly associated with OS. Patients who received a neobladder had better OS likely because of patient selection bias rather than due to a true benefit of the urinary diversion type. Younger patients with fewer comorbidities and more favorable disease are more likely to be offered orthotopic bladder substitutes and, therefore, more likely to have a better survival outcome. 28 To our knowledge this is largest reported series of ICUD. However, several limitations exist. The limitations inherent to a retrospective analysis should be acknowledged. Other limitations are variability among institutions in IRCC in terms of surgical technique, institutional followup protocols and pathology reporting, and the lack of detailed complications and comorbidity data apart from the data presented (supplementary tables 1 and 2, http://jurology.com/). IRCC includes mainly high volume institutions and experienced surgeons, which may limit the generalizability of the results.
CONCLUSIONS
ICUD use dramatically increased in the last decade. The use of ICUD was associated with a higher annual institutional volume of RARC. ICUD has been associated with shorter operative time. Although ICUD was also associated with higher grade complications than ECUD, the rate decreased with time. More surgeons are incorporating ICUD as part of RARC with standardization and evolution of the technique. 
